Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 11.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2023 | 851 | 109 | N/A | N/A | N/A |
9/30/2023 | 1,023 | 191 | -107 | -29 | N/A |
6/30/2023 | 1,283 | 242 | -85 | -3 | N/A |
3/31/2023 | 1,080 | 142 | -72 | 22 | N/A |
12/31/2022 | 1,031 | 138 | 78 | 165 | N/A |
9/30/2022 | 1,158 | 132 | 185 | 318 | N/A |
6/30/2022 | 1,013 | 112 | 142 | 272 | N/A |
3/31/2022 | 1,155 | 213 | 128 | 276 | N/A |
12/31/2021 | 1,140 | 213 | 149 | 269 | N/A |
9/30/2021 | 1,036 | 198 | 139 | 241 | N/A |
6/30/2021 | 997 | 201 | 28 | 108 | N/A |
3/31/2021 | 925 | 188 | 11 | 66 | N/A |
12/31/2020 | 834 | 165 | 71 | 113 | N/A |
9/30/2020 | 901 | 191 | 120 | 151 | N/A |
6/30/2020 | 874 | 165 | 197 | 229 | N/A |
3/31/2020 | 980 | 204 | N/A | N/A | N/A |
12/31/2019 | 1,029 | 227 | 229 | 269 | N/A |
9/30/2019 | 848 | 151 | 174 | 217 | N/A |
6/30/2019 | 837 | 151 | 220 | 261 | N/A |
3/31/2019 | 678 | 91 | N/A | N/A | N/A |
12/31/2018 | 742 | 112 | 141 | 180 | N/A |
9/30/2018 | 632 | 95 | 69 | 110 | N/A |
6/30/2018 | 521 | 78 | -3 | 41 | N/A |
3/31/2018 | 510 | 77 | -11 | 42 | N/A |
12/31/2017 | 498 | 75 | -18 | 43 | N/A |
9/30/2017 | 575 | 109 | N/A | 80 | N/A |
6/30/2017 | 652 | 142 | N/A | 117 | N/A |
3/31/2017 | 637 | 141 | N/A | 129 | N/A |
12/31/2016 | 622 | 139 | N/A | 141 | N/A |
9/30/2016 | 615 | 136 | N/A | 131 | N/A |
6/30/2016 | 607 | 134 | N/A | 121 | N/A |
3/31/2016 | 593 | 131 | N/A | 109 | N/A |
12/31/2015 | 579 | 128 | N/A | 96 | N/A |
9/30/2015 | 556 | 125 | N/A | 102 | N/A |
6/30/2015 | 532 | 122 | N/A | 107 | N/A |
3/31/2015 | 501 | 120 | N/A | 98 | N/A |
12/31/2014 | 471 | 118 | N/A | 88 | N/A |
9/30/2014 | 464 | 111 | N/A | N/A | N/A |
6/30/2014 | 412 | 96 | N/A | 105 | N/A |
3/31/2014 | 446 | 98 | N/A | N/A | N/A |
12/31/2013 | 416 | 87 | N/A | 89 | N/A |
9/30/2013 | 367 | 76 | N/A | N/A | N/A |
6/30/2013 | 307 | 65 | N/A | 71 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 1349 über der Sparquote liegt (2%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 1349 schneller wachsen werden als der Markt Hong Kong
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1349 in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 1349 schneller wachsen werden als der Markt von Hong Kong.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 1349 schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 1349 in 3 Jahren voraussichtlich hoch sein wird